Previous studies have proposed that raloxifene can act via both ER-isoforms, inhibiting signaling pathways such as RAS/MAPK and PI3K/Akt that induce cell cycle arrest and induce apoptosis in various forms of cancers, including breast and prostate cancer [23,24]. This evidence concerns the gene ESR1 and Familial prostate cancer.